Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and ...

Abbott Labs' key product line in its diabetes care segment is the FreeStyle Libre, a portfolio of continuous glucose monitoring (CGM) devices that allow diabetes patients to keep track of their ...

Abbott's stock price has been doing well ... Growth in this segment was fueled by innovations like the FreeStyle Libre CGM system, which generated $1.6 billion in quarterly sales.

Lingo is based on Abbott’s FreeStyle Libre continuous glucose monitoring technology. Abbott’s consumer biowearable, Lingo, is available for consumers 18 years and older not on insulin.

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

Lingo is based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology 1, now used by more than 6 million people with diabetes globally 1. "There is a great deal of ...

However, as the company is gaining a high level of synergies from its continued development within the CGM space, we expect market sentiment to recover in the near future. Designed to track glucose in ...